ArticleDiscover oncology2026
Isthmic papillary thyroid microcarcinoma: clinicopathological features and prognostic factors following isthmusectomy based on tumor size stratification.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to compare clinicopathological features and recurrence risk in clinically node-negative (cN0) solitary isthmic papillary thyroid microcarcinoma (PTMC) ≤ 5 mm and > 5 mm in diameter treated with isthmusectomy, and to identify predictors of recurrence.
methodsA retrospective review was performed of 201 cN0 patients with solitary isthmic PTMC who underwent isthmusectomy between 2018 and 2024. Patients with preoperative high-risk features were excluded. Subgroup analysis compared clinicopathological characteristics between the ≤ 5 mm (n = 107) and > 5 mm (n = 94) groups. Univariate and multivariate Cox models were used to identify factors associated with recurrence-free survival (RFS).
resultsSignificant differences were observed between the two groups in tumor size (p < 0.001), central lymph node metastasis (CLNM) (p = 0.009), microscopic extrathyroidal extension(mETE) (p < 0.001), and BRAF
conclusionThis study demonstrated that isthmic PTMC tumors > 5 mm were associated with a higher risk of recurrence. In addition, CLNM, especially a metastatic CLNs > 3, may have prognostic significance and should be considered in surgical decision-making for isthmic PTMC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.